XORTX Initiates GMP Manufacturing Of XORLO™ For Dual Dossier

For QA directors and regulatory leads tracking late-stage CMO strategy, XORTX Therapeutics has structured its manufacturing program for XORLO™ (oxypurinol) to serve two functions simultaneously: generating GMP clinical supply for the XRX-OXY-102 two-part study and accumulating the validation and stability data required to support an eventual NDA submission.

Contract production of pure oxypurinol drug substance, synthesised via the company's proprietary pathway, is now underway. XORTX is working with its contract manufacturing partner on commercial-scale tablet batches, with validation and stability data from those runs expected to form a core component of the regulatory dossier. The approach compresses the typical sequential timeline by treating clinical-supply batches as prospective process validation evidence, a model that demands rigorous batch record alignment with 21 CFR Part 211 and ICH Q10 quality system requirements from the outset.

The XRx-026 program targets gout patients who cannot tolerate first-line xanthine oxidase inhibitors. Allopurinol intolerance affects an estimated 3–5% of the patient population, and febuxostat carries a boxed cardiovascular warning that has constrained prescribing. XORLO™ is positioned as an alternative in that gap. The US gout population stands at approximately 9.2 million, with global prevalence projected to rise 70% over the next 25 years, according to published epidemiological data.

From a manufacturing governance standpoint, the dual-use batch strategy places early pressure on change control and comparability protocols. Any deviation between clinical-supply batches and the commercial-scale runs intended for NDA submission will require documented bridging, and stability data generated now must be placed on a schedule consistent with ICH Q1A(R2) to be usable at filing. Plant heads overseeing similar CMO arrangements should note that the timeline between first GMP batch and NDA-ready stability package typically spans 24–36 months under accelerated and long-term conditions.

XORTX has indicated it will provide further updates on its regulatory and clinical strategy in the coming weeks, with NDA filing remaining a stated strategic priority for the XRx-026 program.

Source: XORTX Therapeutics Inc. via GlobeNewswire, September 10, 2026.